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Dseveral confounders including, potentially, differences in
arrhythmia pathophysiology. A subanalysis of the mitral
valve cohort attempted to correct for this, but the reduced
study numbers further decreased the statistical power of
this analysis.
In summary, we found that PVI is associated with lower
efficacy than more extensive left atrial lesion sets and that
the addition of right atrial lesions to an extended left atrial
lesion set does not improve efficacy, but increases the rate of
pacemaker implantation for sinus dysfunction. Given the
limitations outlined above, our results are certainly not de-
finitive. However, inasmuch as our study does describe
a substantial real-world experience with a variety of lesion
sets in a representative cardiac surgical population with AF,
we believe that our findings are worth pursuing in a more
rigorous way. We eagerly await the results of an ongoing
National Institutes of Health trial studying the efficacy of
left atrial and biatrial lesion sets in patients with AF who
are undergoing mitral valve surgery.References
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Dr Ralph J. Damiano (St Louis, Mo). Dr Soni, I congratulate
you on a beautiful presentation and for both rigorously looking
at your data and acknowledging the limitations of this study. I
also thank you for providing me with your slides before your talk.
In this work, DrArgenziano and colleagues have presented a ret-
rospective review of 305 patients undergoing primarily concomi-
tant surgical AF ablation. They examined the impact of the
lesion set performed on outcomes at 3, 6, and 12 months. The prin-
cipal conclusion of this study was that the efficacy of their biatrial
lesion set (BeLA) was similar to that of an extended left atrial le-
sion set (eLA), albeit the incidence of pacemaker implantation was
higher in patients who had right atrial lesions. I think this is an in-
teresting finding and certainly suggests the need for further study.
However, it is very difficult to interpret your data and almost im-
possible to draw any definitive conclusions.
The principal problem is that your 2 groups, patients with bia-
trial lesion sets and patients who just had various different left
atrial lesion patterns alone, were very different in terms of their de-
mographics, their operative characteristics, and the ablation tech-
nology that was used to create the lesions. Moreover, the 2 groups
had, as you showed in one of your slides, significantly different left
atrial lesion patterns. In the biatrial group (BeLA), only 5% of pa-
tients had PVI alone on the left side, whereas 60% of the patients in
the left-sided alone group had just PVI as their left atrial lesion set.
I would suggest that the marked differences between these 2
groups suggests there was fairly significant uncontrolled selection
biases in how you decided what to do and patient and procedural
differences that likely have influenced your results.
My first question for you is whether you performed any case-
matched comparison or tried to do a propensity analysis to control
for these marked differences between the 2 groups.rdiovascular Surgery c Volume 145, Number 2 361
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study, we attempted to do a propensity analysis to account for dif-
ferences among groups, which is themain limitation of a retrospec-
tive study. However, owing to the limited number of patients in the
subgroupings of lesion sets, we were unable to perform a propen-
sity analysis. In lieu of this, we adjusted for differences in patient
populations using a stepwise backward multivariate logistic re-
gression. To further adjust for confounders, we did a subanalysis
of biatrial versus left lesion sets in patients who had concomitant
valve surgery. In this cohort, there were no differences in baseline
characteristics among the groups. Our analysis in our mitral valve
cohort corroborated our findings that we presented in our larger co-
hort. As we expand our patient cohort over time and increase our
study power, we will revisit this finding with respect to the general
cohort as well as the various subgroups.
Dr Damiano. I agree. As you accumulate more patients in your
series, it would be interesting to do a more detailed analysis.
The other problem, and you acknowledge this, is that the fol-
low-up in reporting of your results does not follow the recommen-
dations of both the 2007 and 2012 expert consensus statements on
surgical and catheter ablation. Success has to be defined as free-
dom from both AF and atrial flutter, and I would add atrial tachy-
cardia at 12 months. And freedom from arrhythmia has to be off
antiarrhythmic drugs. Not controlling for the use of antiarrhythmic
drugs, particularly in this population, would completely confuse
your results. Many of these patients came in never having been
on antiarrhythmic drugs because they were primarily being re-
ferred for correction of valvular or coronary disease.
If you used the correct end point, which would be freedom from
both atrial tachyarrhythmias and antiarrhythmic drugs at 12
months, would you still have had the same results?
Dr Soni. With respect to antiarrhythmic drugs, that is some-
thing that we are currently evaluating. In the absence of continuous
rhythm monitoring, by using spot electrocardiograms, we are go-
ing to overestimate our success. Furthermore, presenting outcomes
with respect to rhythm instead of rhythm and freedom from antiar-
rhythmic drugs will also tend to overestimate success. However,
inasmuch as the incidence of paroxysmal AF is the same in the var-
ious groups, I would not expect that we overestimated rhythm suc-
cess in 1 group as compared with another. Thus, although this topic
will need to be revisited, we would expect our findings to be
representative.
Dr Damiano.We have found that with relatively low incidence
of recurrence of AF, if you use a stricter end point, which is requir-
ing patients to be off antiarrhythmic drugs, it is much easier to dis-
cern differences between groups.
I would ask my next quick question for you. You obviously had
some patients who had prolonged monitoring. The consensus
statement defined that the minimum acceptable follow-up is
24-hour Holter monitoring. Can you separate the patients who
had at least 24-hour Holter monitoring and reanalyze your data?
Would this change your results?
Dr Soni. That is something that we are taking a look at right
now to further investigate the differences between the patients
who had continuous rhythm monitoring versus those who did not.
Dr Damiano. My final quick question is that pacemaker im-
plantation is a rough and inexact end point in that it depends on
why they had the pacemaker implanted, especially when 96% of362 The Journal of Thoracic and Cardiovascular Surgthe patients had concomitant surgical procedures. Complete heart
block is a complication of valve surgery; it is not a complication of
a maze procedure. There is no way to get complete heart block un-
less you do a lesion set across the atrioventricular node, which is
not described, as far as I know, in any lesion set, nor was it used
in your right atrial lesion pattern.What was the indication for pace-
makers in your series? How many patients had a pacemaker for
complete heart block, which is a complication of the concomitant
surgery, versus how many had a pacemaker put in for sinus node
dysfunction, which is either a complication of the AF or
potentially of the right atrial lesion set?
Dr Soni. The majority of patients had the pacemaker placed for
sinus node dysfunction. This was true in our general cohort as well
as the subanalysis in our mitral valve cohort. There was no differ-
ence in atrioventricular node dysfunction between biatrial or left-
sided lesion set groups. This would indicate that pacemaker
placement was not related to the concomitant procedure but rather
the surgical ablation itself.
Dr Damiano. My point is that it is hard to blame that on the
right atrial lesion set inasmuch as it cannot result in atrioventricu-
lar nodal dysfunction. It can theoretically cause sinus node dys-
function. It may be interesting to look at your data a little more
carefully with this in mind.
Dr Vinay Badhwar (Pittsburgh, Pa). We, like others, support
your interest in homogeneity in reporting, and so I congratulate
you for that.
As you know, tricuspid annular dimension may affect the deci-
sion to perform a tricuspid valve repair concomitantly at the time
of a maze procedure. Have you looked at the tricuspid annular di-
mension in your cohort of patients who had biatrial lesion sets as
well as those with left atrial only lesion sets? How many of those
patients had a tricuspid valve repair and was this a factor in
prompting the biatrial lesion set? If not, have you looked at late in-
cidence of return of tricuspid regurgitation in your patient cohort in
both groups and has this changed how you approach patients now,
particularly in those with a tricuspid annular dimension approach-
ing or greater than 4 cm?
Dr Soni. The concomitant procedure played a role in determin-
ing the extent of the ablation. That is, when there was a reason to
open the right atrium or, for that matter, the left atrium, a more lim-
ited lesion set was often performed. You raise a very interesting
question with regard to the tricuspid valve. Patients who received
concomitant tricuspid valve surgery actually represented a very
small proportion of patients in our cohort. Furthermore, our data-
base is a retrospective database. Although some of our data were
collected prospectively with regard to operative data, we do not
have data regarding the preoperative tricuspid valve annular di-
mension, so we have not taken a look at that. Moving forward, it
would interesting evaluate that in the future.
Dr Takashi Nitta (Tokyo, Japan). I have 1 comment and a ques-
tion. We did an intraoperative mapping study in the patients with
AF to examine how the right atrium plays a role in sustenance
of AF. The results were presented in this meeting and the paper
was published in this Journal in 2005.
Most of the patients with paroxysmal AF showed a focal ac-
tivation arising from the pulmonary vein and the right atrium, in-
dicating the left atrium only lesion set would be enough to
terminate AF. However, three quarters of the patients withery c February 2013
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dicating the biatrial lesion set would be necessary to eliminate
AF. From our data, I believe that the patients who underwent
the left atrium only lesion set still have the substrate for AF in
the right atrium and should be carefully followed up for the
recurrence of AF.
In our mapping study, most of the patients who showed a right
atrial reentry had a dilated right atrium, only the dilated left atrium.
Did you examine the effect of the size of the right atrium on the
results of the left atrium only lesion set?
Dr Soni. Would you please clarify your question?
Dr Nitta. To develop the right atrial reentry, the size of the right
atrium is more important than the left atrial size. Did you measure
the size of the right atrium?
Dr Soni.Again, that is not something that we had measured and
recorded in our database. However, we are currently taking a look
at echocardiographic characteristics in both of our groups and see
how that might have affected our outcomes.
DrEzzeldinMostafa (Cairo, Egypt). I actually have a comment
that is similar to that of my previous colleague about the morphol-
ogy. I guess you have to add to the title, ‘‘in nonrheumatic pa-
tients,’’ because rheumatic patients have a giant right atrium and
a giant left atrium and sometimes rheumatic carditis to the right
atrium, actually necessitating the right atrial maze. That is why
we should add ‘‘in nonrheumatic patients.’’
My question concerns the protocol you are using. Does the pro-
tocol contain amiodarone in intraoperative and postoperative man-
agement to maintain the sinus rhythm, or do you not add
amiodarone?The Journal of Thoracic and CaDr Soni. Just to make sure I understand, you are asking about
the antiarrhythmic regimen after surgery?
Dr Mostafa. Intraoperatively and postoperatively.
Dr Soni.We found that postoperative arrhythmia is not predic-
tive of long-term rhythm success in our cohort. Postoperatively, we
treat our patients with a class 1, 2, or 3 antiarrhythmic for 6 weeks.
At our 6-week return visit, if they are in sinus rhythm at that point,
we stop antiarrhythmic therapy. If they are not in sinus rhythm, the
termination of their antiarrhythmic therapy is left up to the discre-
tion of their cardiologist. Intraoperatively, we do not use
amiodarone.
Dr Mostafa. What about the nonrheumatic pathology? In the
rheumatic pathology, I do not find that an isolated left atrial lesion
is complete for the revision. I guess a biatrial maze should be
added.
Dr Soni. With regard to rheumatic pathology, that represents
a very small percentage of patients in our cohort. We would not
be able to look at that with any sort of definitive answer. When
we repeated the analysis in our mitral valve cohort, we found the
same results in our larger cohort.
Dr Mostafa. Thank you.
Dr Craig R. Smith (New York, NY). I have 1 quick question for
my colleagues. In your conclusions you mention completeness as
having some influence on the outcome. Remind us how you
defined or measured completeness.
Dr Soni. The completeness was with regard to the extent of the
left lesion set. A more extensive lesion set as defined by the addi-
tion of a mitral valve annulus lesion to PVI with or without an LAA
lesion is predictive of success.rdiovascular Surgery c Volume 145, Number 2 363
